コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nicity, disease duration, and treatment with immunosuppressive agents).
2 ycophenolic acid (MPA), is widely used as an immunosuppressive agent.
3 ecause FTY720 is generally regarded as a new immunosuppressive agent.
4 e to rapamycin (RAPA), a "tolerance-sparing" immunosuppressive agent.
5 sage to >40 mg/day and/or the addition of an immunosuppressive agent.
6 its and to have filled a prescription for an immunosuppressive agent.
7 many studies currently are ongoing with this immunosuppressive agent.
8 ssive activity and could be beneficial as an immunosuppressive agent.
9 ces the total cumulative dose of this potent immunosuppressive agent.
10 Thus WY14,643, a fibrate, is a profound immunosuppressive agent.
11 tabolite of leflunomide, a recently approved immunosuppressive agent.
12 in combination with the use of conventional immunosuppressive agent.
13 ids, appears to be the single most effective immunosuppressive agent.
14 h-dose corticosteroids plus a broad-spectrum immunosuppressive agent.
15 ng monoclonal antibody being developed as an immunosuppressive agent.
16 l or for the design of an original series of immunosuppressive agent.
17 nabled disease control and tapering of other immunosuppressive agents.
18 cells under stress following treatment with immunosuppressive agents.
19 s (DSA-PCs) appear resistant to conventional immunosuppressive agents.
20 reased with the increased potency of current immunosuppressive agents.
21 rovided new targets for developing potential immunosuppressive agents.
22 ns and further evaluation of action-specific immunosuppressive agents.
23 y T cells, and targets of current and future immunosuppressive agents.
24 ulation and are suppressed by currently used immunosuppressive agents.
25 ssary and potentially harmful treatment with immunosuppressive agents.
26 m antimalarial agents to corticosteroids and immunosuppressive agents.
27 uggest that they may have potential as novel immunosuppressive agents.
28 ia) in 528 kidney recipients using different immunosuppressive agents.
29 salicylate and corticosteroids, and on novel immunosuppressive agents.
30 -phosphate (S1P) receptor agonists are novel immunosuppressive agents.
31 idely in the clinic as anti-inflammatory and immunosuppressive agents.
32 closely linked with the development of newer immunosuppressive agents.
33 dequately to a number of currently available immunosuppressive agents.
34 ly recognized, and treated with conventional immunosuppressive agents.
35 tary approach to conventional treatment with immunosuppressive agents.
36 ment includes immunoglobulin replacement and immunosuppressive agents.
37 ation with traditional anti-inflammatory and immunosuppressive agents.
38 hniques and the development of more powerful immunosuppressive agents.
39 litis is managed with corticosteroids and/or immunosuppressive agents.
40 ed, however, that these disorders respond to immunosuppressive agents.
41 n (mTOR) such as rapamycin have been used as immunosuppressive agents.
42 tumor growth and are influenced by different immunosuppressive agents.
43 of renal function if treated with additional immunosuppressive agents.
44 e exposed to higher portal concentrations of immunosuppressive agents.
45 ifficult to control with currently available immunosuppressive agents.
46 es reproducibly induced or inhibited by both immunosuppressive agents.
47 MHC mismatch without the long-term need for immunosuppressive agents.
48 ertensive medications and the institution of immunosuppressive agents.
49 TLs retain their function in the presence of immunosuppressive agents.
50 tiglaucoma medications, and chemotherapeutic/immunosuppressive agents.
51 nologic rejection, despite the use of potent immunosuppressive agents.
52 effectiveness of the drug and possible newer immunosuppressive agents.
53 tructural regions of HLA molecules are novel immunosuppressive agents.
54 iviral therapy and reduced administration of immunosuppressive agents.
55 such as ruxolitinib, have been developed as immunosuppressive agents.
56 plantation (LTx), including the influence of immunosuppressive agents.
57 the safety profile of vismodegib with other immunosuppressive agents.
58 managed with oral corticosteroids and other immunosuppressive agents.
59 rally modest efficacy, and can interact with immunosuppressive agents.
60 e interval [CI], 89.7%-95.9%) were receiving immunosuppressive agents.
61 erved for NMSC and NHL in those treated with immunosuppressive agents.
62 which need to be recognized and managed with immunosuppressive agents.
63 ibody+ sera (in vitro ADCC), with or without immunosuppressive agents.
64 ing systemic corticosteroids and second-line immunosuppressive agents.
65 spitalization, she was treated with multiple immunosuppressive agents.
66 tapering steroids and/or adding nonbiologic immunosuppressive agents.
67 l donor HLA matching and use of prophylactic immunosuppressive agents.
68 ypically caused by cytotoxic chemotherapy or immunosuppressive agents.
69 novel biomarkers and therapeutic targets for immunosuppressive agents.
70 g allospecific regulatory effects of diverse immunosuppressive agents.
75 ineurin inhibitors (CNIs) are the first-line immunosuppressive agents administered after liver transp
76 without ESRD and without need for additional immunosuppressive agents after TLI was 19% (4 of 21).
80 potent synergistic interactions between the immunosuppressive agents and antifungal drugs against ma
81 have been developed as antiinflammatory and immunosuppressive agents and are currently undergoing te
82 as been attributed to a novel combination of immunosuppressive agents and avoidance of steroids; howe
83 ncreasingly important with widespread use of immunosuppressive agents and broad-spectrum antibiotics.
84 standard dose glucocorticoids and additional immunosuppressive agents and conversely steroid-sparing
85 Immunosuppression involves the nature of the immunosuppressive agents and individual differences in p
87 -specific treatments are available, although immunosuppressive agents and terminal complement pathway
88 t physicians, given the increasing number of immunosuppressive agents and the balance between rejecti
89 radox between the antifungal activity of the immunosuppressive agents and the occurrence of fungal in
90 the data available on the risk of individual immunosuppressive agents and their ability to prevent dn
92 s had been treated with at least 3 different immunosuppressive agents, and 5 patients had previously
93 gs are widely used as antileukemic drugs and immunosuppressive agents, and 6-thioguanosine triphospha
95 he majority of IBD patients, those receiving immunosuppressive agents, and especially those receiving
96 erapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune globuli
102 ase series provides compelling evidence that immunosuppressive agents are effective at providing long
103 responses such as with anti-inflammatory or immunosuppressive agents are either ineffective, as the
106 condary infection who are being treated with immunosuppressive agents are most at risk for poor outco
109 e, which are well-established anticancer and immunosuppressive agents, are extensively metabolized by
111 e informed that taking pyridostigmine and/or immunosuppressive agents as well as smoking cessation mi
112 een highly active antiretroviral therapy and immunosuppressive agents as well as the potential for hi
114 or later were analyzed to determine whether immunosuppressive agents at the time of first transplant
115 teroids or therapy with corticosteroids plus immunosuppressive agents (azathioprine, cyclophosphamide
117 hibitors are imperfect long-term maintenance immunosuppressive agents because of frequent and irrever
120 red an entity nonresponsive to prednisone or immunosuppressive agents, but it has become apparent ove
121 phritis seems to be a reduction or change of immunosuppressive agents, but this may increase the inhe
122 cocorticoids are potent antiinflammatory and immunosuppressive agents by virtue of their repression o
123 with corticosteroids and other antirheumatic/immunosuppressive agents can preserve hearing and vestib
126 sulfan, cyclophosphamide, or fludarabine and immunosuppressive agents CTLA4-Ig + anti-CD40L or anti-(
128 ited by treatment of infected cells with the immunosuppressive agent cyclosporin A (CsA), HIV-1 infec
135 peutic modulation of psoriasis with targeted immunosuppressive agents defines inflammatory genes asso
137 As LPL may be a target of the commonly used immunosuppressive agent dexamethasone, full elucidation
138 he one transplant recipient not treated with immunosuppressive agents died with anemia and acute vire
140 These findings demonstrate that specific immunosuppressive agents differentially alter the cutane
142 rednisone (</=10 mg/day), antimalarials, and immunosuppressive agents; dosages were required to be st
143 nd the use of more focused and less globally immunosuppressive agents during established rejections m
144 ich target human T cells, are widely used as immunosuppressive agents during treatment of kidney allo
146 and pyrimidine synthesis, is an experimental immunosuppressive agent effective in the prevention/cont
148 ed cancer risk is associated with the use of immunosuppressive agents, especially calcineurin inhibit
150 ry experiments reveal that the commonly used immunosuppressive agent FK-506 can inhibit TRPC6 activit
152 city of ethonafide might make it a promising immunosuppressive agent for clinical use in treating MS
153 at ILT3-Fc acts through BCL6 and is a potent immunosuppressive agent for reversing the onset of allo-
156 rat islets to various concentrations of five immunosuppressive agents for 48 and 24 hr, respectively,
160 ipients who had previously been treated with immunosuppressive agents for primary renal disease.
162 ce suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in hepatocel
164 hosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good respo
165 ccination was 59% (61/104) in patients using immunosuppressive agents (groups 1-3) vs 81% (30/37) in
166 ng MTX monotherapy, those receiving biologic immunosuppressive agents had neither an increased nor de
167 mmune disease requiring systemic steroids or immunosuppressive agents, had no active non-infectious p
173 the treatment of choice for IgG4-RHP because immunosuppressive agents have shown variable efficacy in
174 (TAC) and sirolimus (SRL), two commonly used immunosuppressive agents, have demonstrated contrasting
175 ors against conversion to GMG were receiving immunosuppressive agents (HR 0.42, 95% CI 0.19-0.97) and
177 phenolate mofetil (MMF) has become a popular immunosuppressive agent in pediatric renal transplantati
178 izumab), which has proven to be a successful immunosuppressive agent in solid organ and bone marrow t
179 proliferation and is well established as an immunosuppressive agent in solid organ transplantation.
180 Anti-CD3 immunotoxins are broad-spectrum immunosuppressive agents in a wide range of organ transp
181 rom treatment with corticosteroids and other immunosuppressive agents in addition to plasma exchange
183 ons also associated with lack of response to immunosuppressive agents in children with steroid-resist
184 morrhagic Retinal Vasculitis with aggressive immunosuppressive agents in collaboration with rheumatol
185 apse; or requirements for steroids and other immunosuppressive agents in Crohn disease or ulcerative
187 fficacious addition to therapy with standard immunosuppressive agents in patients with refractory chi
189 led trials have failed to support the use of immunosuppressive agents in pediatric IgA nephropathy an
190 ients with uveitis, use of noncorticosteroid immunosuppressive agents in selected patients with uveit
191 limus (FK506) is one of the most widely used immunosuppressive agents in SOT recipients, and its immu
192 he large increase in the number of available immunosuppressive agents in the past few years mandates
193 gh concurrent administration of conventional immunosuppressive agents including steroids and calcineu
194 ted over the course of 2 years with numerous immunosuppressive agents, including tumor necrosis facto
196 in the development of PVN, judicious use of immunosuppressive agents is indicated to minimize the oc
200 ical characteristics, drug used (second-line immunosuppressive agent [ISA] or biologicals), and drug
201 teroid treatment have shown good response to immunosuppressive agents known to be effective for artic
203 were closely monitored for trough levels of immunosuppressive agents, laboratory values, and potenti
204 nesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion indepen
205 reviously demonstrated that the experimental immunosuppressive agent leflunomide inhibits production
206 ression of innate and adaptive immunities by immunosuppressive agents limits immunological defense, i
208 ulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanc
209 oids may further increase damage, but use of immunosuppressive agents may protect against disease dam
211 rolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft
212 sphate (MZP) is the active metabolite of the immunosuppressive agent mizoribine and a potent inhibito
213 Here, we demonstrate that, in the absence of immunosuppressive agents, monotherapy with clinical-grad
216 ding NTZ duration >/=2 years (n = 13), prior immunosuppressive agents (n = 8), and reported anti-JC v
217 e has produced an ideal antiinflammatory and immunosuppressive agent, namely glucocorticoids, and it
218 nocompromised hosts, with discontinuation of immunosuppressive agents necessary to prevent morbidity.
219 The renal function and degree of exposure to immunosuppressive agents of patients shedding polyomavir
221 xtensive systemic illness and treatment with immunosuppressive agents often require patients with rhe
222 orticosteroids, antiplatelet drugs and other immunosuppressive agents often used in combination with
224 id organ allografts; however, the effects of immunosuppressive agents on NK cells are not clearly est
228 e might be used alone or in combination with immunosuppressive agents, or as salvage therapy for pati
229 but many patients do not tolerate first-line immunosuppressive agents, or experience ongoing relapses
231 one of the study participants were receiving immunosuppressive agents other than low-dose steroids an
233 e adhesion could be used in conjunction with immunosuppressive agents, potentially leading to safer a
235 hic data; transplant date, type, and source; immunosuppressive agents received at diagnosis; and type
236 roid pulse therapy followed by PSL 45 mg and immunosuppressive agent resulted in a resolution of his
237 ts were treated with immunomodulators and/or immunosuppressive agents, resulting in temporary remissi
241 ctive of TF, including previous transplants, immunosuppressive agent selection, and almost all recipi
242 monotherapy as the reference group, biologic immunosuppressive agents showed neither protective nor d
245 l, followed by lower dose prednisone plus an immunosuppressive agent such as azathioprine or methotre
247 ; thus, the incorporation of non-nephrotoxic immunosuppressive agents, such as sirolimus, may provide
248 Relatively limited experience with other immunosuppressive agents, such as tacrolimus, has been r
249 remission, or receiving the same associated immunosuppressive agents, superiority of PTCY over ATG w
250 y in conjunction with the most commonly used immunosuppressive agents tacrolimus and mycophenolate, a
253 neurin inhibition, ISATX247 is a more potent immunosuppressive agent than cyclosporine in this nonhum
254 Radiation is generally considered to be an immunosuppressive agent that acts by killing radiosensit
255 gs suggest that Dp44mT may serve as a potent immunosuppressive agent that could complicate its use as
259 Human herpesvirus 6 (HHV-6) is a potentially immunosuppressive agent that has been suggested to act a
260 ethyl]-1,3-propanediol hydrochloride) is an immunosuppressive agent that inhibits allograft rejectio
262 CR signaling, has long been recognized as an immunosuppressive agent that inhibits T cell receptor ac
264 nalog DCB-3503 is a potential anticancer and immunosuppressive agent that suppresses the translation
265 duals currently requires potent, nonspecific immunosuppressive agents that are neither completely suc
267 Solid organ transplant recipients receive immunosuppressive agents that make them more susceptible
268 e anti-non gal antibody barrier will require immunosuppressive agents that preferentially inhibit thi
269 erance is giving rise to a new generation of immunosuppressive agents, that can exploit these mechani
270 on of a soluble Gal glycoconjugate and other immunosuppressive agents, the survival of pig hearts in
271 dly important class of anti-inflammatory and immunosuppressive agents, their actions in dendritic cel
273 ipient age, donor age, Child-Pugh class, and immunosuppressive agent to be associated with acute reje
274 Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treat
276 on is incomplete or while they are receiving immunosuppressive agents to prevent or treat graft-versu
277 on to the concomitant and alternative use of immunosuppressive agents to steroid therapy, disease rem
278 mits is recommended, and the contribution of immunosuppressive agents to the development of PTDM is a
279 ted against human T lymphocytes, is a potent immunosuppressive agent used to reverse and more recentl
284 as use of oral glucocorticoids and cytotoxic immunosuppressive agents was associated with significant
286 temic corticosteroid and >/=1 other systemic immunosuppressive agent were enrolled from January 2007
287 ystemic corticosteroids and at least 1 other immunosuppressive agent were enrolled from January 2007
288 long-term safety for this approach, when the immunosuppressive agents were antimetabolites or calcine
292 th active SLE that was resistant to standard immunosuppressive agents were treated with B cell deplet
295 of patients without alterations responded to immunosuppressive agents), whereas clinical features, ag
296 tanding of the interactions between Treg and immunosuppressive agents will be valuable to the effecti
298 porphyrin, and butylated hydroxytoluene), an immunosuppressive agent with antivascular endothelial gr
299 3 are a family of potent macrocyclic polyene immunosuppressive agents with a novel mode of action.
300 ceeding to Tier 2, which comprises a host of immunosuppressive agents with relatively lower response